Approval Year
Substance Class |
Protein
Created
by
admin
on
Edited
Tue Apr 01 18:29:43 GMT 2025
by
admin
on
Tue Apr 01 18:29:43 GMT 2025
|
Protein Sub Type | |
Sequence Type | COMPLETE |
Record UNII |
1PE72K8X46
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
P35372
Created by
admin on Tue Apr 01 18:29:43 GMT 2025 , Edited by admin on Tue Apr 01 18:29:43 GMT 2025
|
PRIMARY | |||
|
1PE72K8X46
Created by
admin on Tue Apr 01 18:29:43 GMT 2025 , Edited by admin on Tue Apr 01 18:29:43 GMT 2025
|
PRIMARY |
From | To |
---|---|
1_142 | 1_219 |
Glycosylation Type | HUMAN |
Glycosylation Link Type | Site |
---|---|
N | 1_9 |
N | 1_12 |
N | 1_33 |
N | 1_40 |
N | 1_48 |
Related Record | Type | Details | ||
---|---|---|---|---|
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Emax = 81% of Fentanyl
EC50
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET | |||
|
PARTIAL AGONIST->TARGET |
[35S]GTP?S Binding, 28.7 +/- 1.1 simulation
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
WEAK AGONIST->TARGET |
Inhibition of forskolin-induced cAMP accumulation
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
INVERSE AGONIST->TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Reported to have 13X the potency of morphine
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed activity
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
An opioid analgesic drug from the thiambutene family, which has around the same potency as morphine.
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
INHIBITOR -> TARGET |
In contrast to naloxone, diprenorphine (0.03 mgkg?1i.p.)reversed equipotent doses of morphine and fentanyl to the same degree. Assay done on SH-SY5Y cells displacing [3H]DIPRENORPHINE.
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
LIGAND->TARGET |
BINDING
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Mini Gi assay. Emax=129 (123-136) relative to Fentanyl. EC50 for Fentanyl=34.6
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Male, Wistar rats
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed activity
|
||
|
AGONIST -> TARGET |
IC50
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Inhibition of cAMP accumulation
|
||
|
AGONIST -> TARGET |
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 2.5
AGONIST
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Blood furanylfentanyl concentrations are expected to be in a range of 1-45 ?g/L in victims of fatal overdosage.[
|
||
|
AGONIST -> TARGET |
Assumed an agonist
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
PARTIAL AGONIST->TARGET |
Emax = 23% of DAMGO
EC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
HUMAN RECEPTOR
AGONIST
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Potency higher than fentanyl (IC50=1.23 NM) fast onset and short duration of action.
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Emax=90% Relative maximum effect induced by stimulation with DAMGO. MOR functionality (EC50) measuring cyclic AMP (cAMP) on CHO-K1 cells.
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
WEAK AGONIST->TARGET | |||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
(+)-isomer
COMPETITIVE INHIBITOR
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Cannot cross blood-brain barrier due to positive charge
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
LIGAND->BINDER |
IC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Mouse hot plate test. 117 times more potent than morphine.
ED50
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
In mouse hot plate test, the antinociceptive ED50 of C8813 was 11.5 ?g/kg, being 591 times and 3.4 times more potent than morphine and fentanyl respectively.
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
RADIOLIGAND->TARGET |
Kd
|
||
|
AGONIST -> TARGET |
Assumed active
|
||
|
INHIBITOR -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Herkinorin is a ?-opioid agonist with more than 100x higher ?-opioid affinity and 50x lower ?-opioid affinity compared to Salvinorin A.
|
||
|
AGONIST -> TARGET |
Ratio to morphine 2.3
EC50
|
||
|
INHIBITOR -> TARGET |
Mu Receptor [3H]DAMGO BINDING INHIBITION
BINDING
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
PARTIAL AGONIST->TARGET |
MOR partial agonists with reduced ?-arrestin-2 recruitment in-vitro. 20-fold more potent than morphine at inhibiting contractions and 100-fold more potent than mitragynine.
EC50
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
3H-DAMGO specific binding to gerbil ccrebellar membranes.
Ki
|
||
|
AGONIST -> TARGET |
Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O-demethylated metabolite M1 to ?-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia and 200 times more potent in ?-opioid binding.
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
PARTIAL AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
PARTIAL AGONIST->TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
The fluorinated MT?45 derivatives have higher apparent potencies (2F?MT?45: 42 nM) than MT?45 (1.3 ?M) for inhibition of cAMP accumulation and ??arrestin2 recruitment (2F?MT?45: 196 nM; MT?45: 23.1 ?M).
EC50
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Emax=94.9 relative to Fentanyl
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Has around 7.5-fold the potency of morphine in animal models.
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Atypical. G-protein activation
EC50
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
INHIBITOR -> TARGET |
ANTAGONIST
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
ED50(mg/kg) = 0.220, Potency ratio to morphine = 1.5, Potency ratio to fentanyl = 0.03
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
RADIOLIGAND->OFF TARGET |
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
The antinociceptive ED50 in mouse hot plate of the two compounds were 11.5 ?g/kg and 13.4 ?g/kg respectively.
Ki
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Lance Ultra cAMP Assay
EC50
|
||
|
AGONIST -> TARGET |
Lance Ultra cAMP Assay
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
IC50 of Fentanyl= 1.23 NM
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Lance Ultra cAMP Assay
EC50
|
||
|
AGONIST -> TARGET |
In vitro data suggest that flunitazene is much less potent than fentanyl. Emax=118% of Fentanyl
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Emax=134% of Fentanyl
EC50
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
TRV0109662 is a weak (EC50= 5 mcM) partial agonist of the human mu-opioid receptor.
PARTIAL AGONIST
EC50
|
||
|
INHIBITOR->OFF-TARGET |
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
NON-INHIBITOR->OFF TARGET |
ED50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Emax=106 of Fentanyl
EC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
INHIBITOR -> TARGET |
IRREVERSIBLE INHIBITOR
|
||
|
AGONIST -> TARGET |
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 4.0
AGONIST
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
Emax =140% of Fentanyl. In vitro data shows that N-desethyl isotonitazene is similar in potency to etonitazene, and approximately 20 times more potent than fentanyl.
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Inhibition of forskolin-induced cAMP accumulation.
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Rat tail withdrawal test. Morphine ED50 3.15. Fentanyl ED50 0.1 mg/mL
ED50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed active
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
An active opioid with potency approximately two times greater than that of fentanyl [unpublished data from L. De Vrieze and C. Stove].
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
An active opioid with potency approximately 25 times greater than that of fentanyl [unpublished data from L. De Vrieze and C. Stove].
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
Very high affinity for receptor
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Butonitazene is tens of times superior to morphine when administered intravenously, as was found in chemical studies in rodents. Emax=103% of Fentanyl. beta-Arrestin assay
EC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Mouse hot plate test. 1516 times more potent than morphine.
ED50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
WEAK AGONIST->TARGET |
Presumed to be weak agonist.
|
||
|
AGONIST -> TARGET |
10 times more potent than Fentanyl.
|
||
|
AGONIST -> TARGET |
Emax 180 of hydromorphone
BIOASSAY (CELLULAR)
EC50
|
||
|
AGONIST -> TARGET |
IC50 of Fentanyl= 1.23 NM
IC50
|
||
|
AGONIST -> TARGET |
Ki
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
RAT OPIOD RECEPTOR; POTENCY RELATIVE TO MORPHINE 2.1
AGONIST
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
POTENCY
|
||
|
AGONIST -> TARGET |
Prolonged exposure methadone induces MOPr internalization comparable with that induced by DAMGO, whereas morphine produces much less MOPr heroin during relapse is due to receptor internalization. The blunting of the response to desensitization not receptor antagonism.
|
||
|
AGONIST -> TARGET |
BINDING
Ki
|
||
|
AGONIST -> TARGET |
IC50 of Fentanyl= 1.23 NM
IC50
|
||
|
AGONIST -> TARGET |
Assumed from being on CDC list
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
EC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Emax=113% relative to Fentanyl
EC50
|
||
|
AGONIST -> TARGET |
Mouse hot plate test. 2600 times more potent than morphine.
ED50
|
||
|
AGONIST -> TARGET |
Structural Modifications
Modification Type | Location Site | Location Type | Residue Modified | Extent | Fragment Name | Fragment Approval |
---|---|---|---|---|---|---|
AMINO ACID SUBSTITUTION | [1_365] [1_377] | DEXFOSFOSERINE | VI4F0K069V | |||
AMINO ACID SUBSTITUTION | [1_372] | THREONINE PHOSPHATE | 3L4WX7B1EI | |||
AMINO ACID SUBSTITUTION | [1_168] | TYROSINE O-PHOSPHATE | 2R86C98KDX |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Molecular Formula | CHEMICAL |
|
||||
MOL_WEIGHT | CHEMICAL |
|